1. Systemic active immunotherapy is shifting from the middle ages to a renaissance period

   • G. Mathé

   Editorial Pages: 149 - 152

2. Immunotherapy of neoplastic diseases with neuraminidase: Contradictions, new aspects, and revised concepts

   • H. H. Sedlacek
   • F. R. Seiler

   General Review Pages: 153 - 163

3. T and B lymphocyte populations of tumor-bearing mice treated with 1,3-bis(chloroethyl)-1-nitrosourea (BCNU) or pyran

   • W. A. Stylos
   • M. A. Chirigos
   • P. J. Lyng

   Original Articles Pages: 165 - 172

4. Cytotoxicity of adherent cells associated with some human tumours and lung tissues

   • B. M. Vose

   Original Articles Pages: 173 - 179

5. Canine osteosarcoma: Results of amputation with and without adjuvant immunotherapy

   • P. L. Weiden
   • R. Storb
   • T. C. Graham

   Original Articles Pages: 181 - 186

6. The use of antifibrin antibodies for the destruction of tumor cells

   • F. H. Lee
   • S. Fujimoto
   • A. H. Sehon

   Original Articles Pages: 187 - 193

7. The use of antifibrin antibodies for the destruction of tumor cells

   • F. H. Lee
   • S. Fujimoto
   • A. H. Sehon

   Original Articles Pages: 195 - 200

8. The use of antifibrin antibodies for the destruction of tumor cells

   • F. H. Lee
   • I. Berczi
   • A. H. Sehon

   Original Articles Pages: 201 - 206

9. Delayed tumor growth caused by a combined treatment with BCG and Pseudomonas aeruginosa

   • N. Kiger
   • J. Schulz
   • G. Mathé

   Short Communication Pages: 207 - 210

10. In vivo immunostimulation by tuftsin

    • I. Florentin
    • M. Bruley-Rosset
    • G. Mathé

    Short Communication Pages: 211 - 216